5 pharma stocks that can offer up to 28% return - Check target price by ICICI Securities
According to ICICI Securities, these stocks can help investors get a return of up to 28 per cent in the next one year.
Amid escalating tensions in the Middle East and weak global trends, investors' wealth has tumbled considerably in the last few days. Amid this, the brokerage firm ICICI Securities has selected a few pharma stocks that are expected to offer good returns. The brokerage firm is bullish on these stocks and said that they can be kept in the portfolio with a long-term perspective.
These stocks include Cipla, Aurobindo, Ajanta Pharma, Piramal Pharma and Abbott India. According to ICICI Securities, these stocks can help investors get a return of up to 28 per cent in the next one year. Check the share price target.
Cipla
Brokerage firm ICICI Securities has given a 'buy' call on Cipla stock. It has set a target price of Rs 1,660 per share. On April 16, 2024, the share price closed at Rs 1379. This means the counter has the potential to give a 21 per cent return.
Aurobindo Pharma
Brokerage firm ICICI Securities has set a target price of Rs 1,270 for Aurobindo shares. On April 16, 2024, the stock had closed at Rs 1,110. Considering this, it has the potential of a 15 per cent return.
Ajanta Pharma
Brokerage firm ICICI Securities has given a 'buy' call on the Ajanta Pharma stock. The target per share is Rs 2,385. On April 16, 2024, the share price had settled at Rs 2,066.
Piramal Pharma
Brokerage firm ICICI Securities has given a 'buy' call on the stock of Piramal Pharma. The target per share is Rs 180. On April 16, 2024, the counter had closed at Rs 141.
Abbott India
Brokerage firm ICICI Securities has given a 'buy' call on Abbott India stock. The target per share is Rs 33,000. On April 16, 2024, the share ended at Rs 26,209.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.